Novan Inc
F:6LUA
Novan Inc
Free Cash Flow
Novan Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Free Cash Flow
-$35.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$19.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$12.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
26%
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$10.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$13B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
$6.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Free Cash Flow?
Free Cash Flow
-35.2m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Free Cash Flow amounts to -35.2m USD.
What is Novan Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-2%
Over the last year, the Free Cash Flow growth was -4%. The average annual Free Cash Flow growth rates for Novan Inc have been -20% over the past three years , -2% over the past five years .
